Literature DB >> 23060924

Expression of the chemokine CCL28 in pleomorphic adenoma and adenolymphoma of the human salivary glands.

Guo-Xin Liu1, Jing Lan, Ying Sun, Yi-Jun Hu, Guang-Shui Jiang.   

Abstract

Recent studies have proposed that the chemokine CCL28 is constitutively expressed by epithelial cells in salivary glands and play an important role in lymphocyte trafficking in oral immunity. To date, there is little information on the expression pattern of CCL28 in salivary gland tumors. The purpose of this study was to determine the expression of CCL28 in pleomorphic adenoma and adenolymphoma and to evaluate its potential function in regulating oral carcinogenesis. Immunohistochemical reactivity revealed CCL28 protein expression in the cytoplasm of acinar epithelial cells, both in tumorous tissues and normal adjacent tissues. The level of CCL28 mRNA was markedly reduced in 70% (28/40) of pleomorphic adenomas, and in 81% (26/32) of adenolymphomas, compared to the normal adjacent tissue. CCL28 protein expression was significantly lower in pleomorphic adenomas (P=0.0027, n=40) and in adenolymphomas (P=0.0003, n=32) compared to their normal adjacent tissues. Additionally, the CCL28 protein levels in saliva in the aforementioned patients were lower than those in healthy volunteers. Our study indicated that the reduced expression of CCL28 could possibly be a strategy by recruiting fewer antitumor immunocompetent cells to salivary glands. The expression and secretion of CCL28 may be associated with the pathogenesis of pleomorphic adenoma and adenolymphoma.

Entities:  

Year:  2012        PMID: 23060924      PMCID: PMC3460308          DOI: 10.3892/etm.2012.544

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  15 in total

1.  CCL28 has dual roles in mucosal immunity as a chemokine with broad-spectrum antimicrobial activity.

Authors:  Kunio Hieshima; Haruo Ohtani; Michiko Shibano; Dai Izawa; Takashi Nakayama; Yuri Kawasaki; Fumio Shiba; Mitsuru Shiota; Fuminori Katou; Takuya Saito; Osamu Yoshie
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

2.  Protein expression of the chemokine, CCL28, in human colorectal cancer.

Authors:  Jan Dimberg; Anders Hugander; Dick Wågsäter
Journal:  Int J Oncol       Date:  2006-02       Impact factor: 5.650

Review 3.  IELs: enforcing law and order in the court of the intestinal epithelium.

Authors:  Hilde Cheroutre
Journal:  Immunol Rev       Date:  2005-08       Impact factor: 12.988

4.  Identification of a novel beta-chemokine, MEC, down-regulated in primary breast tumors.

Authors:  C S Mickanin; U Bhatia; M Labow
Journal:  Int J Oncol       Date:  2001-05       Impact factor: 5.650

5.  A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues.

Authors:  J Pan; E J Kunkel; U Gosslar; N Lazarus; P Langdon; K Broadwell; M A Vierra; M C Genovese; E C Butcher; D Soler
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

Review 6.  Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues.

Authors:  Lisa M Ebert; Patrick Schaerli; Bernhard Moser
Journal:  Mol Immunol       Date:  2004-11-23       Impact factor: 4.407

Review 7.  Chemokines and cancer.

Authors:  Albert Zlotnik
Journal:  Int J Cancer       Date:  2006-11-01       Impact factor: 7.396

8.  Peroxiredoxin I, platelet-derived growth factor A, and platelet-derived growth factor receptor alpha are overexpressed in carcinoma ex pleomorphic adenoma: association with malignant transformation.

Authors:  Ana Paula Dias Demasi; Cristiane Furuse; Andresa B Soares; Albina Altemani; Vera C Araújo
Journal:  Hum Pathol       Date:  2008-11-07       Impact factor: 3.466

9.  Regulated production of the chemokine CCL28 in human colon epithelium.

Authors:  Hiroyuki Ogawa; Mitsutoshi Iimura; Lars Eckmann; Martin F Kagnoff
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-07-08       Impact factor: 4.052

Review 10.  The role of CXC chemokines and their receptors in cancer.

Authors:  Jo Vandercappellen; Jo Van Damme; Sofie Struyf
Journal:  Cancer Lett       Date:  2008-06-24       Impact factor: 8.679

View more
  6 in total

1.  CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion.

Authors:  Junhee Park; Xianglan Zhang; Sun Kyoung Lee; Na-Young Song; Seung Hwa Son; Ki Rim Kim; Jae Hoon Shim; Kwang-Kyun Park; Won-Yoon Chung
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

Review 2.  B cells responses and cytokine production are regulated by their immune microenvironment.

Authors:  Monica I Vazquez; Jovani Catalan-Dibene; Albert Zlotnik
Journal:  Cytokine       Date:  2015-03-02       Impact factor: 3.861

3.  CCL28 promotes breast cancer growth and metastasis through MAPK-mediated cellular anti-apoptosis and pro-metastasis.

Authors:  Xiao Li Yang; Kai Yi Liu; Feng Juan Lin; Hui Min Shi; Zhou Luo Ou
Journal:  Oncol Rep       Date:  2017-07-07       Impact factor: 3.906

Review 4.  CCL28 chemokine: An anchoring point bridging innate and adaptive immunity.

Authors:  Teena Mohan; Lei Deng; Bao-Zhong Wang
Journal:  Int Immunopharmacol       Date:  2017-08-30       Impact factor: 4.932

5.  Genome-wide placental DNA methylation analysis of severely growth-discordant monochorionic twins reveals novel epigenetic targets for intrauterine growth restriction.

Authors:  Maian Roifman; Sanaa Choufani; Andrei L Turinsky; Sascha Drewlo; Sarah Keating; Michael Brudno; John Kingdom; Rosanna Weksberg
Journal:  Clin Epigenetics       Date:  2016-06-21       Impact factor: 6.551

6.  CCL28 mucosal expression in SARS-CoV-2-infected patients with diarrhea in relation to disease severity.

Authors:  Xiufeng Jiang; Xu Wang; Bin Liu; Hui Ding; Mengjun Jiang; Zhenkun Yang; Yaping Dai; Difei Ding; Hui Yu; Shiliang Zhang; Jun Liu; Mingchao Sha; Chunyan Lui; Yuanwang Qiu; Hongzhou Lu; Qinxue Hu
Journal:  J Infect       Date:  2020-08-29       Impact factor: 6.072

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.